Stay updated with breaking news from Multi Arm Optimization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Recent research suggests that adding blood thinners to clot-busting medication after an ischemic stroke may not be necessary, as it does not improve the 90-day outcome.
Researchers presenting preliminary late-breaking science presented on the first day of the American Stroke Association’s International Stroke Conference 2024 reported findings from the highly-anticipated MOST (Multi-Arm Optimization of Stroke Thrombolysis) trial. The results showed that giving blood thinners in addition to clot-busting medications to people with ischemic strokes (clot-caused strokes) did not improve their outcomes 90 days later.
Giving blood thinners in addition to clot-busting medications to people with ischemic strokes (clot-caused strokes) did not improve their outcomes 90 days later, according to preliminary late-breaking science presented today at the American Stroke Association's International Stroke Conference 2024.
Argatroban and eptifibatide were ineffective as adjunctive therapies to thrombolysis in patients with ischemic stroke in the MOST trial.
Phase III trial is the 'disappointing end of a long journey'